Christina R Prescott, Elisabeth J Cohen, Judith S Hochman, Andrea B Troxel, Ying Lu, Alberta Twi-Yeboah, Carlos Lopez Jimenez, Shahzad I Mian, Choulakian Y Mazen, David B Warner, Keith H Baratz, Bennie H Jeng
PURPOSE: The Zoster Eye Disease Study (ZEDS) is the first randomized clinical trial to study the efficacy of long-term (1 year) suppressive valacyclovir treatment on herpes zoster ophthalmicus (HZO) outcomes. This article details the baseline characteristics of participants. SETTING: The study was set at 95 participating clinical centers in 33 states, Canada, and New Zealand. STUDY POPULATION: Immunocompetent adults with a history of a characteristic HZO unilateral rash and documentation of an episode of active dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, or iritis within the preceding year, enrolled in ZEDS from November 2017 to January 2023...
February 27, 2024: Cornea